Organization | TCRCure Biopharma Corp.

TCRCure Biopharma Corp. Report issue

For profit Phase 1 Phase 2

Founded: Beijing China (2016)

Organization Overview

First Clinical Trial

2018

NCT03578406

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Guangdong TCRCure Biopharma Technology Co., Ltd | TCRCure Biopharma Corporation | TCRCure Biopharma Ltd | TCRCure Biopharma Ltd. | TCRCURE BIOPHARMA LTD.CHONGQING | TCRCure Biotech Co., Ltd

Active Ingredients

Drugs in Phase 2 Trials (7)

aldesleukin (proleukin) (1 trial)

ALPP CAR-T (1 trial)

cyclophosphamide (cytoxan) (2 trials)

fludarabine (fludara) (2 trials)

hpv e6-specific tcr-t cell with anti-pd1 auto-secreted element (1 trial)

lmp2 antigen-specific tcr t cells (1 trial)

tcr-t cells (1 trial)

Drugs in Phase 1 Trials (2)

histone h3.3-k27m neoantigen vaccine therapy (1 trial)

hpv e6-specific T cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Endometrial Neoplasms (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Uterine Cervical Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 9